- Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium
- Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
- Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
- Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)
- Lineage Announces Changes to Board of Directors
- Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
- Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
- RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
- RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
More ▼
Key statistics
On Wednesday, Lineage Cell Therapeutics Inc (BT3:STU) closed at 0.925, 21.71% above the 52 week low of 0.76 set on Feb 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.905 |
---|---|
High | 0.925 |
Low | 0.90 |
Bid | 0.955 |
Offer | 0.995 |
Previous close | 0.96 |
Average volume | 0.00 |
---|---|
Shares outstanding | 188.82m |
Free float | 188.01m |
P/E (TTM) | -- |
Market cap | 190.71m USD |
EPS (TTM) | -0.1344 USD |
Data delayed at least 15 minutes, as of May 22 2024.
More ▼